Literature DB >> 18064049

Creating immune privilege: active local suppression that benefits friends, but protects foes.

Andrew L Mellor1, David H Munn.   

Abstract

Natural regulatory mechanisms prevent inappropriate immune activation to self and innocuous foreign antigens. Here, we adapt the notion of immune privilege, which was originally applied to transplanted tissues, to consider how antigenic tumour cells and chronic pathogens might exploit natural regulatory mechanisms to become non-immunogenic. This conceptual approach reveals new mechanistic perspectives that may help to explain the paradoxical persistence of tumours and chronic pathogens, and suggests new opportunities to improve immunotherapy to treat these chronic inflammatory diseases.

Entities:  

Mesh:

Year:  2008        PMID: 18064049     DOI: 10.1038/nri2233

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  142 in total

1.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Authors:  Rikke Baek Sørensen; Sine Reker Hadrup; Inge Marie Svane; Mads Christian Hjortsø; Per Thor Straten; Mads Hald Andersen
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

2.  IDO in human gut graft-versus-host disease.

Authors:  Philippe Ratajczak; Anne Janin; Régis Peffault de Larour; Lisa Koch; Brigitte Roche; David Munn; Bruce R Blazar; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

Review 3.  Advancing islet transplantation: from engraftment to the immune response.

Authors:  R F Gibly; J G Graham; X Luo; W L Lowe; B J Hering; L D Shea
Journal:  Diabetologia       Date:  2011-08-10       Impact factor: 10.122

4.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

5.  Deficient tryptophan catabolism along the kynurenine pathway reveals that the epididymis is in a unique tolerogenic state.

Authors:  Aicha Jrad-Lamine; Joelle Henry-Berger; Pascal Gourbeyre; Christelle Damon-Soubeyrand; Alain Lenoir; Lydie Combaret; Fabrice Saez; Ayhan Kocer; Shigenobu Tone; Dietmar Fuchs; Wentao Zhu; Peter J Oefner; David H Munn; Andrew L Mellor; Najoua Gharbi; Rémi Cadet; R John Aitken; Joël R Drevet
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

6.  Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Authors:  Levi H C Makala; Babak Baban; Henrique Lemos; Ahmed R El-Awady; Phillip R Chandler; De-Yan Hou; David H Munn; Andrew L Mellor
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

7.  Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior.

Authors:  Jason C O'Connor; Marcus A Lawson; Caroline André; Eileen M Briley; Sandra S Szegedi; Jacques Lestage; Nathalie Castanon; Miles Herkenham; Robert Dantzer; Keith W Kelley
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Authors:  Alexander J Muller; Madhav D Sharma; Phillip R Chandler; James B Duhadaway; Mary E Everhart; Burles A Johnson; David J Kahler; Jeanene Pihkala; Alejandro Peralta Soler; David H Munn; George C Prendergast; Andrew L Mellor
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

9.  Pathogenic antibodies are active participants in spinal cord injury.

Authors:  Gregory A Dekaban; Sakina Thawer
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

Review 10.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.